During Oct. 25-26, SAST and SITI jointly held the 18th Golden Bridge Industrial Technology Innovation Conference, with the theme of “Molecular Diagnosis for Tumors and Clinic Data Integration and Application”, which invited experts from China and USA to joint discuss and summarize the scientific frontline and development trends of Molecular Diagnosis for Tumors and Clinical Applications domestic and international as well as to exchange the practices and newest progress of Clinic Data Integration and Application, so as to propel new round strategic cooperation. Mr. Niu Xiaoming, president of SAST and SITI, Mr. Chen Zhen, vice president of Shanghai Tumor Hospital, attended the meeting and delivered opening speeches. Mr. Cao Amin, vice president of SAST, hosted the meeting.

Mr. Niu Xiaming said that cancer was the problem faced by all the human beings, and with the increase of cancer occurrence in the recent years, the discussion topic of “Molecular Diagnosis for Tumors and Clinic Data Integration and Application” was of realistic significance. He pointed out that the research teams at SAST and SITI had been focusing on the researches of this area for a long time and had established innovation partnership with Shanghai Tumor Hospital the previous year. The two parties collected a large quantity of pathology and data from fundamental researches, sequencing technology, as well as cancer pathology, samples, and sequencing data, and the analysis and application of the data would be the next-step important technology method to conquer cancers. He expressed his hope that experts from MD Anderson Medical Center, Hill House Medical Group and relevant experts in China would jointly focus on the topic and discuss about development so that a joint research team would be formed to conquer the problem and exert joint efforts to climb the new highland in the battle against cancers in 21st century.

Mr. Chen Zhen said that both geneticists and doctors at clinics were expecting the early-stage interference and treatment plan to be formed through genome detection for tumors which could satisfy the customized needs of patients. He pointed out that since the signing of “innovation partnership” between Shanghai Tumor Hospital and SITI, the joint team had made good progress in breast cancer genomics. The two sides jointly constructed Joint Laboratory for Clinical Transformation of Precision Medicine for Tumors, carried out deep cooperation of high throughput gene sequencing in the diagnosis and treatment of cancer, which became a success example of industry-research cooperation.

On the meeting, Prof. Xiangwei Wu, Anderson MD Cancer Center, University of Texas, Dr. Lisa Mullineaux, Genomics Alliance, Hillhouse Medical Group, Prof. Huang Wei, director of Bio-Medicine Translational Application Center, SITI, Dr. Stephanie E. Hallam, Genleviate, Mr. Jonathan Sun, CTO, Hillhouse Medical Group, Dr. Zhiheng Yu, kidney expert of Texas Medical Center, and Prof. Zhimin Shao, director of Fudan University Cancer Research Center and director of Breast Surgery, Shanghai Tumor Hospital affiliated to Fudan University, gave lectures on their research dimensions. During the meeting, Prof. Zhimin Shao was awarded the certificate of “Chief Expert, Bio-medicine, SITI”, Dr. Lisa Mullineaux and Dr. Zhiheng Yu were awarded as “Guest Experts, Bio-medicine, SITI”. More than 80 participants from various departments of SITI and social circles attended the meeting.

The next day, the delegation from USA also visited Shanghai Tumor Hospital and Experimental Animal Center and held a discussion in SAST and SITI on the next-step cooperation.